Feed Top Reports Pricing

⌘K

11:33:55·1249d

SECFiling

SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.

AERI· Aerie Pharmaceuticals Inc.

Health Care

Original source

Companies

AERI
Aerie Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Aug 29UpdateCitigroup$15.25
Aug 23UpdateNeedham-
Aug 23UpdateCantor Fitzgerald$15.25
Feb 25UpdateNeedham$14.00
Nov 5UpdateNeedham$22.00
Aug 5UpdateNeedham$24.00

Related

13D/G1168d
SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)
SEC1239d
SEC Form 15-12G filed by Aerie Pharmaceuticals Inc.
NEWS1245d
Aerie Pharmaceuticals's Return On Capital Employed Overview
PR1249d
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business
INSIDER1249d
SEC Form 4: Mchugh Julie returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company to cover taxes
INSIDER1249d
SEC Form 4: Mcgraw Benjamin F Iii returned $640,256 worth of shares to the company (41,984 units at $15.25), closing all direct ownership in the company to satisfy tax liability
INSIDER1249d
SEC Form 4: Mcdonnell Peter J returned $121,924 worth of shares to the company (7,995 units at $15.25), closing all direct ownership in the company (for withholding tax)
INSIDER1249d
SEC Form 4: Kopczynski Casey C. returned $4,273,721 worth of shares to the company (280,244 units at $15.25), closing all direct ownership in the company (withholding tax)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022